The Global Escherichia Coli Testing Market size is estimated at USD 1.36 billion in 2024, and is expected to reach USD 2 billion by 2029, growing at a CAGR of 7.93% during the forecast period (2024-2029).
Escherichia coli are bacterium or germs that are commonly found in the environment, foods in the gut of humans and warm-blooded animals.
The COVID-19 pandemic had a significant impact on the market studied. As per the data from the National Institute of Health published in March 2022, according to evidence-based research and the concepts of antimicrobial stewardship, simultaneous infection of antibiotic-resistant uropathogens in patients with COVID-19 has forced a reconsideration of the administration of broad-spectrum antibiotics. According to a research article by Ahmed Al-Jabir et al., published in the International Journal of Surgery, July 2020, during the COVID-19 pandemic, urological procedures delayed or postponed included urinary tract infections, stress incontinence, overactive bladder (OAB), and neurogenic bladder. As urinary tract infection is caused by E. Coli, the diagnosis was delayed during the pandemic which affected the market growth.
Most of the Escherichia coli strains are harmless but some strains such as Shiga toxin-producing E.coli, can cause severe foodborne disease and are mostly transmitted through consumption of undercooked or raw ground meat products, raw milk, and contaminated raw vegetables and sprouts. Symptoms of the diseases caused by Shiga toxin-producing E.coli (STEC) include abdominal cramps, diarrhoea, bloody diarrhoea (haemorrhagic colitis), fever and vomiting.
In the case of water treatment plants, Escherichia coli is the test organism for finding out the effectiveness of the effluent disinfection treatment process. According to an article published in the Journal of Emerging Infectious Diseases in 2021, Escherichia coli accounts for over 85% of all urinary tract infections. The increasing prevalence of diarrhoea and high government funding are the key factors that drive the growth of the E. coli testing market.
The polymerase chain reaction technique is also used in detecting urinary tract infections caused by E. Coli bacteria. The study published by the National Center for Biotechnology Information in 2019, titled 'Multiplex PCR Based Urinary Tract Infection (UTI) Analysis Compared to Traditional Urine Culture in Identifying Significant Pathogens in Symptomatic Patients', reports that uropathogens were found by PCR in 326 patients, while pathogens were detected by urine culture in 217 patients. The study also demonstrated the accuracy of polymerase chain reactions to diagnose UTIs. Additionally, PCR offers a wide range of applications in a variety of industries. The Human Genome Project (HGP) relied extensively on PCR to determine the sequence of 3 billion base pairs in the human genome. For instance, a PCR technique, called Multiplex PCR, was used to identify Duchenne muscular dystrophy, caused by a gene mutation.
Therefore, with the above-mentioned significance of PCR, the segment is expected to witness strong growth over the forecast period.
The same source as above stated that approximately 40 percent of these infections are caused by the strain Escherichia coli (E. coli) O157:H7, part of the Shiga toxin-producing group of Escherichia coli (E. coli) bacteria (STEC), and other 60 percent of Escherichia coli (E. coli) cases are caused by non-0157:H7 Shiga toxin-producing Escherichia coli (E. coli) (STEC). Moreover, increasing awareness regarding hygiene, and the introduction of advanced testing technologies in this region is fueling the growth of the overall regional market to a large extent.
According to an article published by healthypeople.gov in 2020, in the United States, 1 out of every 25 hospitalized patients is affected by an HAI. Thus, the high incidence rate of HAIs in the United States will drive the attention of the management of healthcare facilities and governments to maintain hygiene in the facility and take preventive measures for the same, thus leading to the lucrative growth of the market. In September 2021, the Center for Diseases Control and Prevention announced to investment of USD 2.1 Billion to Protect Patients and Healthcare Workers from COVID-19 and Future Infectious Diseases. Thus, initiatives help to boost market growth over the forecast period.
Similarly, according to 2020 data by the American Health Association, there were approximately 36.2 million hospital admissions in 2019. Building upon this success and continuing toward the elimination of hospital-acquired infections is critical, and this has contributed to the largest market share of the United States.
Therefore, owing to the above-mentioned factors, the market studied is expected to witness strong growth in the North America region.
This product will be delivered within 2 business days.
Escherichia coli are bacterium or germs that are commonly found in the environment, foods in the gut of humans and warm-blooded animals.
The COVID-19 pandemic had a significant impact on the market studied. As per the data from the National Institute of Health published in March 2022, according to evidence-based research and the concepts of antimicrobial stewardship, simultaneous infection of antibiotic-resistant uropathogens in patients with COVID-19 has forced a reconsideration of the administration of broad-spectrum antibiotics. According to a research article by Ahmed Al-Jabir et al., published in the International Journal of Surgery, July 2020, during the COVID-19 pandemic, urological procedures delayed or postponed included urinary tract infections, stress incontinence, overactive bladder (OAB), and neurogenic bladder. As urinary tract infection is caused by E. Coli, the diagnosis was delayed during the pandemic which affected the market growth.
Most of the Escherichia coli strains are harmless but some strains such as Shiga toxin-producing E.coli, can cause severe foodborne disease and are mostly transmitted through consumption of undercooked or raw ground meat products, raw milk, and contaminated raw vegetables and sprouts. Symptoms of the diseases caused by Shiga toxin-producing E.coli (STEC) include abdominal cramps, diarrhoea, bloody diarrhoea (haemorrhagic colitis), fever and vomiting.
In the case of water treatment plants, Escherichia coli is the test organism for finding out the effectiveness of the effluent disinfection treatment process. According to an article published in the Journal of Emerging Infectious Diseases in 2021, Escherichia coli accounts for over 85% of all urinary tract infections. The increasing prevalence of diarrhoea and high government funding are the key factors that drive the growth of the E. coli testing market.
Escherichia Coli Testing Market Trends
Polymerase Chain Reaction Segment is Expected to be Major Segment in the Escherichia coli Testing Market
The polymerase chain reaction is a scientific procedure for making numerous copies of a given piece of DNA from a sample containing only a small amount of the DNA. It can be used to search for specific mutations in a gene or chromosome, which can aid in the detection and diagnosis of genetic disorders or diseases like cancer. It can also be used to examine DNA fragments from bacteria, viruses, and other microbes to aid in the diagnosis of infections.The polymerase chain reaction technique is also used in detecting urinary tract infections caused by E. Coli bacteria. The study published by the National Center for Biotechnology Information in 2019, titled 'Multiplex PCR Based Urinary Tract Infection (UTI) Analysis Compared to Traditional Urine Culture in Identifying Significant Pathogens in Symptomatic Patients', reports that uropathogens were found by PCR in 326 patients, while pathogens were detected by urine culture in 217 patients. The study also demonstrated the accuracy of polymerase chain reactions to diagnose UTIs. Additionally, PCR offers a wide range of applications in a variety of industries. The Human Genome Project (HGP) relied extensively on PCR to determine the sequence of 3 billion base pairs in the human genome. For instance, a PCR technique, called Multiplex PCR, was used to identify Duchenne muscular dystrophy, caused by a gene mutation.
Therefore, with the above-mentioned significance of PCR, the segment is expected to witness strong growth over the forecast period.
North America is Expected to hold the Market Share is Expected to do Same in the Forecast Period
North America is expected to hold the largest share globally in the Escherichia coli (E. coli) market. According to the North Carolina Department of Health and Human Services 2020 data, every year in the United States, infections caused by Escherichia coli (E. coli) are approximately 265,000 illnesses and about 100 deaths.The same source as above stated that approximately 40 percent of these infections are caused by the strain Escherichia coli (E. coli) O157:H7, part of the Shiga toxin-producing group of Escherichia coli (E. coli) bacteria (STEC), and other 60 percent of Escherichia coli (E. coli) cases are caused by non-0157:H7 Shiga toxin-producing Escherichia coli (E. coli) (STEC). Moreover, increasing awareness regarding hygiene, and the introduction of advanced testing technologies in this region is fueling the growth of the overall regional market to a large extent.
According to an article published by healthypeople.gov in 2020, in the United States, 1 out of every 25 hospitalized patients is affected by an HAI. Thus, the high incidence rate of HAIs in the United States will drive the attention of the management of healthcare facilities and governments to maintain hygiene in the facility and take preventive measures for the same, thus leading to the lucrative growth of the market. In September 2021, the Center for Diseases Control and Prevention announced to investment of USD 2.1 Billion to Protect Patients and Healthcare Workers from COVID-19 and Future Infectious Diseases. Thus, initiatives help to boost market growth over the forecast period.
Similarly, according to 2020 data by the American Health Association, there were approximately 36.2 million hospital admissions in 2019. Building upon this success and continuing toward the elimination of hospital-acquired infections is critical, and this has contributed to the largest market share of the United States.
Therefore, owing to the above-mentioned factors, the market studied is expected to witness strong growth in the North America region.
Escherichia Coli Testing Industry Overview
The Escherichia coli Testing Market is moderately competitive and consists of of several major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently domianting the market are Thermo Fisher Scientific, Alere Inc, Becton, Dickinson and Company, BioMerieux Inc, NanoLogix, Inc, Meridian Bioscience, Bio-Rad Laboratories, CPI International, Inc, Pro-Lab Diagnostics, Inc, IDEXX Laboratories, Inc.Additional Benefits:
- The market estimate (ME) sheet in Excel format
- 3 months of analyst support
This product will be delivered within 2 business days.
Table of Contents
1 INTRODUCTION
4 MARKET DYNAMICS
5 MARKET SEGMENTATION (Market Size - Value in USD million)
6 COMPETITIVE LANDSCAPE
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Becton, Dickinson and Company
- Bio-Rad Laboratories Inc
- Caisson Laboratories, Inc
- Cell Culture Technologies LLC
- Corning Incorporated
- Fujifilm Holdings Corporation
- GE Healthcare
- HiMedia Laboratories Pvt., Ltd
- Lonza Group Ltd
- Merck & Co., Inc
Methodology
LOADING...
